The article discusses the problem of resistance to the anti-malarial artemisinin, and outlines the attempts being made in the Nanomalaria lab to develop nanoparticles that encapsulate drugs which target only infected cells, that not only recover the activity that resistance has built up against but also exhibit fewer the side effects.
Click here to read the article.
